Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PatientCrossroads Resource Report Resource Website 1+ mentions |
PatientCrossroads (RRID:SCR_006279) | PatientCrossroads | data or information resource, patient registry, people resource, portal, topical portal | A trusted third-party gatekeeper of patient data from participants in a rare disease ecosystem, collecting and managing the information in a scalable, cost-effective manner. Each patient registry provides critical disease knowledge which makes that disease easier to study, increasing the probability a treatment can be developed. PatientCrossroads takes a network approach to patient registry programs. Unlike companies that merely sell registry software, we offer a full range of administration, management, and genetic curation services. What does this consolidated, patient-centric approach to patient registries mean? * Patients can more easily find registries and provide their valuable data (including locations of blood and tissue samples as well as reports of diagnoses, disease symptoms, treatment usage, and lifestyle activities) * Patients can be confident in the privacy of their de-identified data and the knowledge that PatientCrossroads does not sell patient data * Researchers and pharmaceutical companies have a larger, more easily accessible pool of potential patients for research studies and clinical trials targeting specific rare diseases * Pharmaceutical companies can collect post-market surveillance data in a more scalable and cost-effective manner * Rare disease advocacy and research foundations can more easily organize their global patient populations for inclusion in trials and studies | disease, treatment, clinical, patient, registry, drug discovery, clinical trial, research study, genetics, biorepository | is parent organization of: NF Registry | Rare disease | nlx_151889 | SCR_006279 | Patient Crossroads | 2026-08-29 11:22:34 | 3 | |||||||
|
EU-AIMS Resource Report Resource Website 1+ mentions |
EU-AIMS (RRID:SCR_003861) | EU-AIMS | consortium, data or information resource, organization portal, portal | Consortium aiming to generate tools that will enhance understanding of autism spectrum disorders (ASD) and pave the way for the development of new, safe and effective treatments for use in both children and adults. For example, the team will gather samples from people bearing certain mutations associated with ASD; this will pave the way for the generation of cell lines that can be used to test treatments. Elsewhere, the researchers will advance the use of brain scans as a tool to boost ASD drug discovery and also identify which people with ASD might respond best to a given drug. The project will also create a pan-European network of clinical sites. As well as making it easier to run clinical trials, this network will create an interactive platform for those with ASD and professionals. By the end of the 5 year project they expect to provide novel validated cellular assays, animal models, new fMRI methods with dedicated analysis techniques, new PET radioligands, as well as new genetic and proteomic biomarkers for patient-segmentation or individual response prediction. They will provide a research network that can rapidly test new treatments in man. These tools should provide their EFPIA partners with an added competitive advantage in developing new drugs for ASD. | basic science, tool development, child, adult human, young human, treatment, diagnose, symptom, clinical, cell line, drug, drug discovery, neuroimaging, mutation, clinical trial, medicine |
is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Pfizer Animal Genetics is related to: King's College London; London; United Kingdom is related to: Birkbeck University of London; London; United Kingdom is related to: Central Institute of Mental Health; Mannheim; Germany is related to: CEA; Gif sur Yvette; France is related to: European Molecular Biology Laboratory is related to: University College London; London; United Kingdom is related to: Pasteur Institute is related to: Karolinska Institute; Stockholm; Sweden is related to: Max-Planck-Gesellschaft is related to: Biomedical University Campus of Rome; Rome; Italy is related to: University of Basel; Basel; Switzerland is related to: Ulm University; Baden-Wurttemberg; Germany is related to: University of Cambridge; Cambridge; United Kingdom is related to: Autism Speaks is related to: GABO:mi is related to: deCODE genetics is related to: Noldus has parent organization: Roche |
Innovative Medicines Initiative ; EFPIA |
nlx_158184 | SCR_003861 | European Autism Interventions - A Multicentre Study for Developing New Medications, European Autism Interventions | 2026-08-29 11:21:40 | 2 | |||||||
|
EARIP Resource Report Resource Website |
EARIP (RRID:SCR_003854) | EARIP | consortium, data or information resource, organization portal, portal | Consortium that convenes asthma experts from across Europe to define research gaps to reduce the impact of asthma. The project activities range from basic cell science research, to assessing and improving European healthcare systems. Their activities include workshops, prioritization exercises, consensus strategies, and the development and publication of a set of recommendations about what's needed to reduce asthma deaths and hospitalizations. The eventual goal is to have a comprehensive R&D roadmap for asthma. EARIP will target a number of asthma research areas to ensure a comprehensive overview of all current research strategies from across Europe is included in the project road map. These include: * Research into biological targets, aiming to discover new targets and better define the role of existing biological targets * Identify new systems, models and tools for phenotypic stratification * Develop better and more efficient healthcare systems across Europe * Define and develop new diagnostic tools * Assess and improve patient self-management systems and provide suggestions for how these can be developed * Identify how to establish a European Innovation Partnership (EIP) for the management of asthma * Establish a European research network of clinical asthma research facilities | biomarker, biological target, tool development, clinical, basic research |
is listed by: Consortia-pedia is related to: Imperial College London; London; United Kingdom is related to: Karolinska Institute; Stockholm; Sweden is related to: European Federation of Allergy and Airways Diseases Patients Associations is related to: European Lung Foundation is related to: University of Athens; Athens; Greece is related to: University of Southampton; Southampton; United Kingdom is related to: Swiss Institute of Allergy and Asthma Research is related to: University of Lodz; Lodz; Poland has parent organization: Asthma UK |
European Union FP7-Health Programme 602077 | nlx_158171 | SCR_003854 | European Asthma Research and Innovation Partnership, European Asthma Research and Innovation Partnership (EARIP) | 2026-08-29 11:21:40 | 0 | |||||||
|
TRANSFoRm Clinical Research Information Model Resource Report Resource Website |
TRANSFoRm Clinical Research Information Model (RRID:SCR_003889) | CRIM | data or information resource, narrative resource, report, standard specification | A clinical research information model for the integration of clinical research covering randomized clinical trials (RCT), case-control studies and database searches into the TRANSFoRm application development. TRANSFoRm clinical research is based on primary care data, clinical data and genetic data stored in databases and electronic health records and employs the principle of reusing primary care data, adapting data collection by patient reported outcomes (PRO) and eSource based Case Report Forms. CRIM was developed using the TRANSFoRm clinical use cases of GORD and Diabetes. Their use case driven approach consisted of three levels of modelling drawing heavily on the clinical research workflow of the use cases. Different available information models were evaluated for their usefulness to represent TRANSFoRm clinical research, including for example CTOM of caBIG, Primary Care Research Object Model (PRCOM) of ePCRN and BRIDG of CDISC. The PCROM model turned out to be the most suitable and it was possible to extend and modify this model with only 12 new information objects, 3 episode of care related objects and 2 areas to satisfy all requirements of the TRANSFoRm research use cases. Now the information model covers Good Clinical Practice (GCP) compliant research, as well as case control studies and database search studies, including the interaction between patient and GP (family doctor) during patient consultation, appointment, screening, patient recruitment and adverse event reporting. | clinical, randomized clinical trial, clinical trial, primary care, genetic, clinical research, electronic health record, model, interoperability |
uses: Clinical Data Interchange Standards Consortium is used by: TRANSFoRm Data Integration Models has parent organization: TRANSFoRm |
nlx_158219 | SCR_003889 | Clinical Research Information Model | 2026-08-29 11:21:46 | 0 | ||||||||
|
TRANSFoRm Resource Report Resource Website 50+ mentions |
TRANSFoRm (RRID:SCR_003888) | TRANSFoRm | consortium, data or information resource, organization portal, portal | Project to develop a ''rapid learning healthcare system'' driven by advanced computational infrastructure that can improve both patient safety and the conduct and volume of clinical research in Europe. Three carefully chosen clinical ''use cases'' will drive, evaluate and validate the approach to the ICT (information and communications technology) challenges. The project will build on existing work at international level in clinical trial information models (BRIDG and PCROM), service-based approaches to semantic interoperability and data standards (ISO11179 and controlled vocabulary), data discovery, machine learning and electronic health records based on open standards (openEHR). TRANSFoRm will extend this work to interact with individual eHR systems as well as operate within the consultation itself providing both diagnostic support and support for the identification and follow up of subjects for research. The approach to system design will be modular and standards-based, providing services via a distributed architecture, and will be tightly linked with the user community. Four years of development and testing will end with a fifth year that will be dedicated to summative validation of the project deliverables in the Primary Care setting. In order to support patient safety in both clinical and research settings, significant ICT challenges need to be overcome in the areas of interoperability, common standards for data integration, data presentation, recording, scalability, and security., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | clinical, interoperability, healthcare system, healthcare, electronic health record, clinical data, metadata standard, aggregator |
has parent organization: King's College London; London; United Kingdom is parent organization of: TRANSFoRm Clinical Data Integration Model is parent organization of: TRANSFoRm Clinical Research Information Model is parent organization of: TRANSFoRm Data Integration Models |
European Union FP7 247787 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158218 | SCR_003888 | Translational Research and Patient Safety In Europe | 2026-08-29 11:21:41 | 60 | ||||||
|
PharmaCog Resource Report Resource Website 10+ mentions |
PharmaCog (RRID:SCR_003878) | PharmaCog | consortium, data or information resource, organization portal, portal | Project aiming to tackle bottlenecks in Alzheimer''''s disease research and drug discovery by developing and validating new tools to test candidate drugs for the treatment of symptoms and disease in a faster and more sensitive way. They will provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. By bringing together databases of previously conducted clinical trials and combining the results from blood tests, brain scans and behavioral tests, the scientists will develop a ''''signature'''' that gives more accurate information on the progression of the disease and the effect of candidate drugs than current methods do. The scientists will conduct parallel studies in laboratory models, healthy volunteers and patients in order to better predict good new drugs as early as possible. This will enable them, for instance, to find out how memory loss in Alzheimer''''s disease can be simulated in healthy volunteers, for example with sleep deprivation or drugs that temporarily affect the memory, in order to test the effect of candidate-medicines early in the drug development process. | drug, biomarker, drug discovery, model, tool development, drug development, medicine, clinical, pre-clinical, pharmacology, disease progression, cognitive impairment |
is listed by: Consortia-pedia is related to: Merck is related to: Janssen Research and Development is related to: Roche is related to: Eisai is related to: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France is related to: Alzheimer Europe is related to: French National Center for Scientific Research is related to: Greek Association of Alzheimers Disease and Related Disorders is related to: August Pi i Sunyer Biomedical Research Institute; Barcelona; Spain is related to: National Institute of Health and Medical Research; Rennes; France is related to: Mario Negri Institute for Pharmacological Research; Milan; Italy is related to: University of Murcia; Murcia; Spain is related to: Catholic University of the Sacred Heart; Milan; Italy is related to: University of Foggia; Foggia; Italy is related to: University of Genoa; Genoa; Italy is related to: University of Perugia; Perugia; Italy is related to: University of Verona; Verona; Italy is related to: University of Leipzig; Saxony; Germany is related to: Lille 2 University of Health and Law; Lille; France is related to: University of Exeter; Exeter; United Kingdom is related to: Innovative Concepts in Drug Development is related to: AlzProtect is related to: Qualissima is related to: Exonhit Therapeutics is related to: University of Bristol; Bristol; United Kingdom is related to: European Medicines Agency has parent organization: Lille 2 University of Health and Law; Lille; France has parent organization: Alzheimer Europe has parent organization: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France |
Innovative Medicines Initiative 115009; EFPIA |
nlx_158206 | SCR_003878 | Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development, Pharma-Cog | 2026-08-29 11:22:01 | 13 | |||||||
|
Patients to Trials Consortium Resource Report Resource Website |
Patients to Trials Consortium (RRID:SCR_003877) | Patients2Trials Consortium | community building portal, consortium, data or information resource, organization portal, people resource, portal, service resource | A three-member pharmaceutical industry consortium that aims to provide a new platform to improve access to information about clinical trials for patients and providers. The platform aims to enhance the existing clinicaltrials.gov by providing more detailed and patient-friendly information about available trials and embedding a machine-readable target health profile to improve the ability of healthcare software to match individual health profiles with applicable clinical trials. Using clinicaltrials.gov as its foundation and Eli Lilly''''s Application Programming Interface (API), the consortium is focused on creating an open platform to make this data more amenable to patients and providers, as well as creating an opportunity to integrate a patient''''s electronic health record into the clinical trial matching service. This feature will allow patients to search for trials using their own Blue Button data. The following features are planned add-ons to clinicaltrials.gov: * Target Profile is a machine readable query, that can be executed against an electronic file (or record) with patient health data such as an Electronic Health Record (EHR), an Electronic Medical Record (EMR) or Personally Controlled Health Record (PCHR) * Augmented Content is public, IRB approved information about the study that has not been published on clinicaltrials.gov, and that is shared with / targeted for patients with a matching Target Profile. The following are the incremental goals of the consortium: * Advancement of the Lilly API platform to support read/write interaction and additional data objects and information. * The initial 3 sponsor organizations - Lilly, Pfizer and Novartis - will upload Target Profiles for a select set of clinical trials. A Target Profile is a machine interpretable description of the characteristics of patients who may qualify for that trial i.e. a query that can be executed against a patient''''s electronic health record or personal health record. Additionally, sponsors of clinical research studies will also be able to upload Augmented Content to the Lilly Platform to supplement information on clinicaltrials.gov with additional, patient-focused information about the study, e.g., a study brochure and practical information on how to contact investigational sites. * A matching service, developed by Corengi, will compare Target Profiles to a de-dentified personally controlled health record (PCHR), represented by patient''''s Blue Button Plus CCDA XML document. * Integration into a patient community platform from Avado for providing the patient PCHR and presenting the results of the match service. The patient will be able to explore the respective matching studies for additional information and next steps such as contacting a nearby investigator clinic or hospital. The first demo of the prototype was made available on June 2014, built on a database of anonymized patient health records from different clinical research studies sponsored by Lilly, Novartis, and Pfizer. Other website: http://portal.lillycoi.com/ | drug development, tool development, clinical trial, clinical, patient profile, clinical research study, health record, platform, database |
uses: ClinicalTrials.gov is listed by: Consortia-pedia is related to: Pfizer Animal Genetics is related to: Corengi |
Open unspecified license, Public | nlx_158205 | SCR_003877 | p2t consortium | 2026-08-29 11:21:46 | 0 | |||||||
|
Charles River Laboratories Resource Report Resource Website 10000+ mentions |
Charles River Laboratories (RRID:SCR_003792) | CRL | biomaterial supply resource, material resource, organism supplier | Commercial organism provider selling mice, rats and other model animals. American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. (Wikipedia) | RIN, Resource Information Network, pre-clinical, clinical, pharmaceutical, medical device, biotechnology, drug, drug discovery, RRID Community Authority |
is listed by: Resource Information Network is related to: Oncotest works with: International Mouse Strain Resource |
SCR_013551, grid.452317.6, nif-0000-00462, nlx_158088, Wikidata: Q28974283 | https://ror.org/01tasya06 | SCR_003792 | Charles River Laboratories Inc., Charles River, Charles River Laboratories International Inc. | 2026-08-29 11:22:00 | 11510 | |||||||
|
BioClinica Resource Report Resource Website 100+ mentions |
BioClinica (RRID:SCR_003789) | BioClinica | commercial organization | Pennsylvania-based company supporting pharmaceutical and medical device innovation with imaging core lab, EDC, IVR / IWR, CTMS, and supply chain forecasting and optimization. Its initial service was medical imaging for clinical trials. It is used to capture, collect, control quality, provide blinded reading services to the final delivery to the sponsor company and to the FDA or EMEA if required for medical images in a wide range of imaging modalities. (Wikipedia) | clinical trial, pharmaceutical, medical device, medical imaging, cardiac safety, clinical | Crossref funder ID: 100007742, ISNI: 0000 0004 0602 1531, Wikidata: Q4914605, grid.430790.9, nlx_158082 | https://ror.org/03t95yr58 | SCR_003789 | BioClinica Inc. | 2026-08-29 11:22:00 | 101 | ||||||||
|
AirPROM Resource Report Resource Website |
AirPROM (RRID:SCR_003827) | AirPROM | consortium, data or information resource, organization portal, portal | Consortium focused on developing computer and physical models of the airway system for patients with asthma and chronic obstructive pulmonary disease (COPD). Developing accurate models will better predict how asthma and COPD develop, since current methods can only assess the severity of disease. They aim to bridge the gaps in clinical management of airways-based disease by providing reliable models that predict disease progression and the response to treatment for each person with asthma or COPD. A data management platform provides a secure and sustainable infrastructure that semantically integrates the clinical, physiological, genetic, and experimental data produced with existing biomedical knowledge from allied consortia and public databases. This resource will be available for analysis and modeling, and will facilitate sharing, collaboration and publication within AirPROM and with the broader community. Currently the AirPROM knowledge portal is only accessible by AirPROM partners. | model, airway system, lung, consortium, clinical, imaging, respiratory system, tissue sample, airway model, genomic, gas diffusion mri, airway development, function, physiological, genetic, computational model, gene-environment interaction |
is listed by: Consortia-pedia has parent organization: European Lung Foundation |
European Union FP7 | nlx_158142 | SCR_003827 | Airway Disease Predicting Outcomes through Patient Specific Computational Modelling | 2026-08-29 11:21:44 | 0 | |||||||
|
BioSHaRE Resource Report Resource Website 10+ mentions |
BioSHaRE (RRID:SCR_003811) | BIOSHARE-EU | consortium, data or information resource, narrative resource, organization portal, portal, standard specification | A consortium of leading biobanks and international researchers from all domains of biobanking science to ensure the development of harmonized measures and standardized computing infrastructures enabling the effective pooling of data and key measures of life-style, social circumstances and environment, as well as critical sub-components of the phenotypes associated with common complex diseases. The overall aim is to build upon tools and methods available to achieve solutions for researchers to use pooled data from different cohort and biobank studies. This, in order to obtain the very large sample sizes needed to investigate current questions in multifactorial diseases, notably on gene-environment interactions. This aim will be achieved through the development of harmonization and standardization tools, implementation of these tools and demonstration of their applicability. BioSHaRE researchers are collaborating with P3G, the Global Alliance for Genomics and Health, IRDiRC (International Rare Diseases Research Consortium), H3Africa and other organizations on the development of an International Code of Conduct for Genomic and Health-Related Data Sharing. A draft version is available for external review. Generic documents have been prepared covering areas of biobanking that are of major importance. SOPs have been finalized for blood withdrawal (SOPWP5001blood withdrawal), manual blood processing (SOPWP5002blood processing), shipping of biosamples (SOPWP5003shipping) and withdrawal, processing and storage of urine samples (SOPWP5004urine). | gene-environment interaction, life-style, social circumstance, environment, phenotype, disease, biobank, socio-economic factor, data sharing, gene, clinical |
is listed by: Consortia-pedia has parent organization: University of Groningen; Groningen; Netherlands is parent organization of: BioResource Impact Factor |
European Union FP7 | nlx_158110 | SCR_003811 | Biobank Standardisation and Harmonisation for Research Excellence, Biobank Standardisation and Harmonisation for Research Excellence in the European Union | 2026-08-29 11:21:39 | 22 | |||||||
|
Canadian Consortium on Neurodegeneration in Aging Resource Report Resource Website |
Canadian Consortium on Neurodegeneration in Aging (RRID:SCR_003846) | CCNA | consortium, data or information resource, organization portal, portal | Consortium that will be the premier research hub for all aspects of research involving neurodegenerative diseases that affect cognition in aging - including Alzheimer's disease. They will promote high impact, inter-institutional and interdisciplinary collaboration through a pan-Canadian approach, and will position Canadian researchers to lead and participate in a new wave of national and international initiatives with congruent goals. The consortium focuses research into the basic mechanisms of neurodegenerative diseases, accelerating the development of tools that can be used to assist in the diagnosis and treatment of the diseases. The intended outcome of these tools is to improve the quality of life and services patients with neurodegenerative diseases. As part of the Canadian contribution to the International Collaborative Research Strategy for Alzheimer's disease, the consortium brings together Canadian government agencies (federal and provincial), foundations, pharmaceutical companies, philanthropists and international stakeholders to identify if there are common causes and risk factors to neurodegenerative diseases. The consortium is focused on three themes: * Primary Prevention aimed at preventing the disease from developing * Secondary Prevention focused on delaying the clinical manifestations of the already developing disease * Quality of Life designed for helping individuals, caregivers and the health system in the context of a clinically developed disease. | cognition, biomarker, primary prevention, secondary prevention, quality of life, clinical, late adult human, prevention |
is listed by: Consortia-pedia has parent organization: Institute of Aging - CIHR |
Canadian Institutes of Health Research ; Alzheimer Society of Canada ; Alzheimers Research UK |
nlx_158160 | SCR_003846 | Canadian Consortium on Neurodegeneration in Aging (CCNA) | 2026-08-29 11:22:01 | 0 | |||||||
|
BiomarCaRE Resource Report Resource Website 10+ mentions |
BiomarCaRE (RRID:SCR_003841) | BIOMARCARE, BiomarCaRE | consortium, data or information resource, organization portal, portal | EU funded consortium including over 30 partner from academia and industry. BiomarCaRE aims to determine the value of established and emerging biomarkers to improve risk estimation of cardiovascular disease in Europe. BiomarCaRE relies on an exceptional resource of large scale epidemiological cohorts with long term follow-up and available bio specimens based on the population of the MORGAM Project as well as several cardiovascular disease cohorts and clinical trials. | drug, biomarker, diagnostic, cardiovascular risk, phenotype, ultrasound, mri, clinical, epidemiological, risk prediction, lifestyle, risk factor, heart | is listed by: Consortia-pedia | European Union FP7 | nlx_158154, SCR_013677 | SCR_003841 | BiomarCaRE.EU, Biomarker for Cardiovascular Risk Assessment in Europe (BIOMARCARE), Biomarker for Cardiovascular Risk Assessment in Europe | 2026-08-29 11:21:45 | 28 | |||||||
|
Nephrology Nursing Certification Commission Resource Report Resource Website |
Nephrology Nursing Certification Commission (RRID:SCR_003994) | NNCC | data or information resource, organization portal, portal, training resource | Organization that established credentialing mechanisms to promote patient safety and to improve the quality of care provided to nephrology patients. There is a diversity of examinations providing the opportunity for certification at various levels of education, experience, and areas of practice within nephrology nursing. All of the certification examinations are endorsed by American Nephrology Nurses'''' Association (ANNA). The Commission recognizes the value of education, administration, research, and clinical practice in fostering personal and professional growth and currently provides six examinations to validate clinical performance: * The Certified Dialysis Nurse examination * The Certified Dialysis LPN/LVN examination * The Certified Nephrology Nurse examination * The Certified Clinical Hemodialysis Technician * The Certified Clinical Hemodialysis Technician - Advanced * The Certified Nephrology Nurse - Nurse Practitioner | nephrology, kidney, nursing, certification, clinical, dialysis, hemodialysis |
is related to: American Nephrology Nurses Association is related to: Kidney Health Initiative |
Kidney disease | nlx_158407 | SCR_003994 | Nephrology Nursing Certification Board, NNCB | 2026-08-29 11:21:51 | 0 | |||||||
|
Comprehensive Biomarker Center Resource Report Resource Website |
Comprehensive Biomarker Center (RRID:SCR_003901) | CBC | commercial organization | Commercial organization that discovers, validates & analyzes genomic biomarkers with a focus on body fluid samples. Take advantage of their proven expertise in biomarker signature development and speed up your biomarker studies. | biomarker, clinical research organization, genomic biomarker, genomic, diagnostic, testing, bodily fluid, clinical, dna, rna, dna extraction, rna extraction, microarray, next-generation sequencing, validation, microrna | is related to: READNA | nlx_158236 | SCR_003901 | febit, febit GmbH, Comprehensive Biomarker Center Gmbh | 2026-08-29 11:21:41 | 0 | ||||||||
|
Hospira Resource Report Resource Website 100+ mentions |
Hospira (RRID:SCR_003985) | Hospira | commercial organization | American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.Provider of injectable drugs and infusion technologies and global leader in biosimilars. From September 2015 Hospira is part of Pfizer. | drug, infusion pump, software, device, contract manufacturing, clinical, intravenous set |
is related to: Kidney Health Initiative is related to: Pfizer Inc. |
nlx_158395 | SCR_003985 | Hospira Inc., | 2026-08-29 11:21:51 | 122 | ||||||||
|
ERA-EDTA Resource Report Resource Website 10+ mentions |
ERA-EDTA (RRID:SCR_003982) | ERA-EDTA | community building portal, data or information resource, portal | An association of European kidney specialists whose objective is advancement of medical science and of clinical work in nephrology, dialysis, renal transplantation, hypertension and related subjects. They aim at providing up-to-date knowledge, exclusively based on scientific data, independent from governments'' policies and from any influence of the industry. It is registered in England and Wales, but its area of activity mainly covers Europe and the Mediterranean area. | kidney, dialysis, transplant, nephrology, medical, clinical, renal transplantation, hypertension | is related to: Kidney Health Initiative | Kidney disease | nlx_158389 | SCR_003982 | European Renal Association - European Dialysis and Transplant Association, European Renal Association - European Dialysis & Transplant Association | 2026-08-29 11:21:51 | 22 | |||||||
|
Quartz Bio Resource Report Resource Website |
Quartz Bio (RRID:SCR_003919) | QBIO | commercial organization | A Swiss service and consulting company specialized in the computational analysis of biomarker data from clinical trials. Their technical expertise spans across multiple biomaker technological platforms such as genetics, transcriptomics, protein assays and cellular assays. Quartz Bio is a spin-off of Merck Serono with the capital of the company entirely owned by its employees. | clinical, bioinformatics, medicine, biomarker, clinical trial, data analysis | is related to: PRECISESADS | nlx_158280 | SCR_003919 | Quartz Bio S.A. | 2026-08-29 11:22:01 | 0 | ||||||||
|
Qualissima Resource Report Resource Website |
Qualissima (RRID:SCR_003941) | Qualissima | commercial organization | A Research as a Service (RaaS) Company founded by a Clinical Pharmacologist and Neuropsychiatrist that offers to its partners (health products industries and public research), 3 platforms: * Clinical research (CRO and SMO) * Scientific & regulatory consulting * Online surveys (Web portal) Their Research & Development profile allows them to propose innovative concepts such as : * Patient-Leader studies * Translational research studies (fMRI, innovative biomarkers, modeling, ...) * Behavioral parameters as biomarkers studies Qualissima also proposes proof of concept studies, proof of activities studies, medical devices studies and observational studies. | neurodegeneration, central nervous system, cardiology, dermatology, infectiology, cancerology, biomarker, clinical trial, clinical | is related to: PharmaCog | grid.492092.4, nlx_158328 | https://ror.org/008zpgd78 | SCR_003941 | Qualissima GmbH | 2026-08-29 11:21:49 | 0 | |||||||
|
Arbor Research Collaborative for Health Resource Report Resource Website 1+ mentions |
Arbor Research Collaborative for Health (RRID:SCR_003972) | Arbor Research | nonprofit organization | A not-for-profit research organization committed to improve patient care through research that shapes medical policies and practice. In particular, they conduct health outcomes research on chronic disease and end-stage organ failure, with expertise in biostatistical analysis, clinical practice, health economics, public policy, database management and integration, and project coordination. Through research projects that are national and global in scope, their scientific collaborations provide valuable and timely information to the worldwide health care community. They are a leader in interdisciplinary health outcomes and policy research focused on reducing the health and economic burden of chronic diseases and improving the delivery of care. | health outcome, patient care, clinical, policy, nephrology, statistics, kidney, transplant, dialysis, epidemiology, public health, clinical practice, policy development, medical payment system | is related to: Kidney Health Initiative | Kidney disease, Organ failure, Chronic disease | grid.413857.c, nlx_158379, ISNI: 0000 0004 0628 9837 | https://ror.org/043qmbk61 | SCR_003972 | URREA, University Renal Research and Education Association | 2026-08-29 11:21:50 | 3 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.